[go: up one dir, main page]

PE20180241A1 - Adenovirus oncolitico que codifica una proteina b7 - Google Patents

Adenovirus oncolitico que codifica una proteina b7

Info

Publication number
PE20180241A1
PE20180241A1 PE2017002327A PE2017002327A PE20180241A1 PE 20180241 A1 PE20180241 A1 PE 20180241A1 PE 2017002327 A PE2017002327 A PE 2017002327A PE 2017002327 A PE2017002327 A PE 2017002327A PE 20180241 A1 PE20180241 A1 PE 20180241A1
Authority
PE
Peru
Prior art keywords
protein
virus
oncolytic adenovirus
compositions
treatment
Prior art date
Application number
PE2017002327A
Other languages
English (en)
Inventor
Brian Robert Champion
Alice Claire Noel Bromley
Original Assignee
Psioxus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1507419.8A external-priority patent/GB201507419D0/en
Priority claimed from GBGB1516936.0A external-priority patent/GB201516936D0/en
Priority claimed from GBGB1522013.0A external-priority patent/GB201522013D0/en
Application filed by Psioxus Therapeutics Ltd filed Critical Psioxus Therapeutics Ltd
Publication of PE20180241A1 publication Critical patent/PE20180241A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere a un adenovirus oncolitico de replicacion competente con selectividad para celulas cancerosas, en donde el adenovirus comprende un transgen bajo el control de un promotor endogeno al virus, en donde el transgen comprende una secuencia de ADN que codifica una proteina B7 o un fragmento activo de la misma, composiciones que comprenden los mismos, metodos para generar el virus, y uso del virus y composiciones en el tratamiento, particularmente en el tratamiento de cancer
PE2017002327A 2015-04-30 2016-04-29 Adenovirus oncolitico que codifica una proteina b7 PE20180241A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1507419.8A GB201507419D0 (en) 2015-04-30 2015-04-30 Virus
GBGB1516936.0A GB201516936D0 (en) 2015-09-24 2015-09-24 Virus
GBGB1522013.0A GB201522013D0 (en) 2015-12-14 2015-12-14 Virus

Publications (1)

Publication Number Publication Date
PE20180241A1 true PE20180241A1 (es) 2018-01-31

Family

ID=56008588

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2017002327A PE20180241A1 (es) 2015-04-30 2016-04-29 Adenovirus oncolitico que codifica una proteina b7
PE2018000519A PE20181140A1 (es) 2015-04-30 2016-04-29 Adenovirus oncolitico que codifica una proteina b7

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2018000519A PE20181140A1 (es) 2015-04-30 2016-04-29 Adenovirus oncolitico que codifica una proteina b7

Country Status (31)

Country Link
US (6) US11000559B2 (es)
EP (2) EP3391892A1 (es)
JP (3) JP6931229B2 (es)
KR (4) KR20180118249A (es)
CN (2) CN108396015B (es)
AU (3) AU2016256582B2 (es)
BR (2) BR122018004815A2 (es)
CA (1) CA2984038C (es)
CL (2) CL2017002731A1 (es)
CO (1) CO2017010831A2 (es)
CY (1) CY1122833T1 (es)
DK (1) DK3288573T3 (es)
EA (1) EA037611B1 (es)
ES (1) ES2780366T3 (es)
HR (1) HRP20200439T1 (es)
HU (1) HUE048320T2 (es)
IL (3) IL284375B (es)
LT (1) LT3288573T (es)
MX (1) MX2017013684A (es)
MY (1) MY183703A (es)
PE (2) PE20180241A1 (es)
PH (1) PH12017501942A1 (es)
PL (1) PL3288573T3 (es)
PT (1) PT3288573T (es)
RS (1) RS60105B1 (es)
SA (2) SA520412637B1 (es)
SG (3) SG11201708604TA (es)
SI (1) SI3288573T1 (es)
SM (1) SMT202000222T1 (es)
WO (1) WO2016174200A1 (es)
ZA (1) ZA201801589B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2671558C2 (ru) 2013-06-14 2018-11-02 Псайоксус Терапьютикс Лимитед Режим введения и составы для аденовирусов типа в
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
ES2661132T3 (es) 2013-10-25 2018-03-27 Psioxus Therapeutics Limited Adenovirus oncolíticos armados con genes heterólogos
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
PE20180241A1 (es) 2015-04-30 2018-01-31 Psioxus Therapeutics Ltd Adenovirus oncolitico que codifica una proteina b7
CN108884139A (zh) 2015-11-02 2018-11-23 戊瑞治疗有限公司 Cd80胞外域多肽及其在癌症治疗中的用途
EA201891022A1 (ru) 2015-12-17 2019-01-31 Псайоксус Терапьютикс Лимитед Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
DK3436591T5 (da) * 2016-03-31 2024-09-16 The European Molecular Biology Laboratory Adenovirale coat-protein-afledte transportvehikler
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
MX2019002328A (es) 2016-08-29 2019-07-04 Psioxus Therapeutics Ltd Adenovirus armado con captador biespecífico de linfocitos t (bite).
EP3507304B1 (en) * 2016-09-02 2024-04-03 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
US11253558B2 (en) 2016-09-27 2022-02-22 Sator Therapeutics LLC Optimized oncolytic viruses and uses thereof
WO2018083257A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083259A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
US12350303B2 (en) 2017-02-03 2025-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Oncolytic virus therapy
KR20190139216A (ko) 2017-04-28 2019-12-17 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
IL270876B2 (en) 2017-05-25 2024-06-01 Univ Central Florida Res Found Inc Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
BR112019024813A2 (pt) * 2017-05-26 2020-06-09 Epicentrx Inc adenovírus recombinantes portando transgenes
ES2952601T3 (es) * 2017-06-01 2023-11-02 Akamis Bio Ltd Virus oncolítico y método
WO2019147921A1 (en) * 2018-01-26 2019-08-01 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
GB201801614D0 (en) * 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
WO2019173334A1 (en) * 2018-03-05 2019-09-12 The Schepens Eye Research Institute, Inc. Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration
CN118001307A (zh) * 2018-03-30 2024-05-10 藤堂具纪 肿胀发生抑制型溶瘤病毒
CN119955743A (zh) * 2018-09-10 2025-05-09 上海锦斯生物技术有限公司 修饰的溶瘤病毒、其组合物和用途
SG11202108449SA (en) * 2019-03-05 2021-09-29 Amgen Inc Use of oncolytic viruses for the treatment of cancer
EP3725323A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
EP3970754A4 (en) * 2019-05-14 2023-08-02 Oncolys BioPharma, Inc. METHOD OF ADMINISTRATION OF ONCOLYTIC VIRUS TO TUMOR TISSUE AND DEVICE FOR ADMINISTRATION
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
AU2021287998A1 (en) 2020-06-11 2023-02-02 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
GB202102049D0 (en) * 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
CN113544263B (zh) * 2021-06-03 2022-12-06 上海允英生物医药科技有限公司 溶瘤病毒载体及其应用
JP2024536835A (ja) 2021-09-23 2024-10-08 サジタリウス バイオ，インコーポレーテッド アデノウイルス及びアデノウイルスの使用方法
US20250215452A1 (en) * 2022-03-25 2025-07-03 Universität Zürich Adenoviral Mediated Targeting of Activated Immune Cells
WO2024243578A1 (en) 2023-05-25 2024-11-28 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
PL179877B1 (pl) 1993-07-13 2000-11-30 Rhone Poulenc Rorer Sa Zdefektowany replikacyjnie adenowirus, linia komórkowa do infekowania zdefektowanym adenowirusem oraz srodek farmaceutyczny PL PL PL PL PL PL PL PL PL PL
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
EP1036183B1 (en) 1997-02-20 2007-10-03 The Johns Hopkins University School Of Medicine Mutations in atp-dependent transposition proteins that reduce target-site specificity
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
AU767975B2 (en) * 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
EP1137792B9 (en) 1998-12-09 2007-12-12 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
EP1054064B2 (en) 1999-05-17 2009-12-16 Crucell Holland B.V. Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
DE60018920T2 (de) 1999-06-01 2006-04-13 University Of Washington, Seattle Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
EP1252322B2 (en) 2000-01-21 2009-03-04 BioVex Limited Herpes virus strains for gene therapy
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
AU2001265154A1 (en) 2000-05-31 2001-12-11 Genvec, Inc. Method and composition for targeting an adenoviral vector
US7459153B2 (en) 2001-01-04 2008-12-02 Wadell Goeran Viral vectors for gene therapy
US20050175589A1 (en) * 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
JP2005515784A (ja) * 2002-02-01 2005-06-02 トランジェーヌ、ソシエテ、アノニム Ｐｏｄに関連した細胞活性を調節するためのアデノウイルスベクター
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
AU2003223775A1 (en) 2002-04-30 2003-11-17 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
CN1705740B (zh) * 2002-10-15 2013-07-24 佩尔·松内·霍尔姆 具有反向基因表达的腺病毒及其应用
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
WO2004087930A1 (en) 2003-03-28 2004-10-14 Saint Louis University Adenovirus replication-competent vectors expressing trail
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
WO2005010149A2 (en) 2003-07-18 2005-02-03 Onyx Pharmaceuticals, Inc. Subgroup b adenoviral vectors for treating disease
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
US20080292592A1 (en) 2004-04-30 2008-11-27 Sunil Chada Oncolytic Adenovirus Armed with Therapeutic Genes
CN1997746B (zh) 2004-05-26 2012-09-26 普西奥克瑟斯医疗有限公司 用于治疗癌症的嵌合腺病毒
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20060292682A1 (en) * 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
CN101068933A (zh) * 2004-08-25 2007-11-07 细胞基因系统有限公司 用于肿瘤细胞增强转导的纤维修饰的腺病毒载体
JP2008511336A (ja) * 2004-09-01 2008-04-17 アメリカ合衆国 免疫原性が増加したアデノウイルスベクターをインビボで用いる方法
US20090208924A1 (en) 2004-12-01 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Generation of Replication Competent Viruses for Therapeutic Use
CA2620495A1 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
DE102005055128B4 (de) 2005-11-15 2015-04-02 Universität Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
WO2008080003A2 (en) 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof
EP2296678A4 (en) 2008-05-27 2012-03-21 Oncolytics Biotech Inc MODULATION OF INTERSTITIAL PRESSURE AND ONCOLYTIC VIRUS RELIEF AND DISTRIBUTION
CN101381742A (zh) 2008-10-23 2009-03-11 浙江理工大学 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
ES2385251B1 (es) * 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
US20120283318A1 (en) * 2009-10-05 2012-11-08 Mei Ya-Fang Replicating viral vectors for gene therapy
CA2808389C (en) 2010-08-16 2019-11-12 Salk Institute For Biological Studies Adenoviral assembly method
CA2812096A1 (en) * 2010-09-24 2012-03-29 Oncos Therapeutics Oy Adenoviral vectors and methods and uses related thereto
CN103221544A (zh) 2010-09-24 2013-07-24 昂克斯治疗有限公司 编码单克隆抗-ctla-4抗体的溶瘤腺病毒载体
JP2015507604A (ja) 2011-11-14 2015-03-12 リジェネレイティブ サイエンシーズ， エルエルシー 懸濁粒子送達システムおよび方法
CN102586327B (zh) 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
CN105407902A (zh) 2013-03-05 2016-03-16 贝勒医学院 溶瘤病毒
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
ES2661132T3 (es) * 2013-10-25 2018-03-27 Psioxus Therapeutics Limited Adenovirus oncolíticos armados con genes heterólogos
AU2014352749A1 (en) 2013-11-22 2016-06-09 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
GB201406608D0 (en) * 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) * 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
WO2016146894A1 (en) 2015-03-17 2016-09-22 Tilt Biotherapeutics Oy Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
PE20180241A1 (es) * 2015-04-30 2018-01-31 Psioxus Therapeutics Ltd Adenovirus oncolitico que codifica una proteina b7
EA201891022A1 (ru) 2015-12-17 2019-01-31 Псайоксус Терапьютикс Лимитед Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
KR20180118198A (ko) 2016-03-18 2018-10-30 난트셀, 인크. 수지상 세포 감염을 위한 멀티모달 벡터(multimodal vector for dendritic cell infection)
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
MX2019002328A (es) 2016-08-29 2019-07-04 Psioxus Therapeutics Ltd Adenovirus armado con captador biespecífico de linfocitos t (bite).
AU2017345764A1 (en) 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
ES2952601T3 (es) * 2017-06-01 2023-11-02 Akamis Bio Ltd Virus oncolítico y método
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Also Published As

Publication number Publication date
JP7162929B2 (ja) 2022-10-31
KR102854512B1 (ko) 2025-09-04
IL255286A0 (en) 2017-12-31
SA520412637B1 (ar) 2022-03-01
US10322152B2 (en) 2019-06-18
BR112017023171A2 (pt) 2018-07-17
PH12017501942A1 (en) 2018-03-19
EP3288573A1 (en) 2018-03-07
EP3288573B1 (en) 2020-02-12
SG11201708604TA (en) 2017-11-29
CY1122833T1 (el) 2021-05-05
JP6931229B2 (ja) 2021-09-01
IL258044B (en) 2021-07-29
JP2021176339A (ja) 2021-11-11
AU2018201446B2 (en) 2020-05-28
EP3391892A1 (en) 2018-10-24
IL284375A (en) 2021-07-29
CN107690479A (zh) 2018-02-13
RS60105B1 (sr) 2020-05-29
AU2016256582A8 (en) 2018-01-18
CA2984038C (en) 2023-01-03
US20210338753A1 (en) 2021-11-04
IL284375B (en) 2022-07-01
PT3288573T (pt) 2020-03-25
KR20250134212A (ko) 2025-09-09
US10849945B2 (en) 2020-12-01
HUE048320T2 (hu) 2020-07-28
LT3288573T (lt) 2020-03-25
BR122018004815A2 (pt) 2019-09-10
AU2018201446A1 (en) 2018-03-29
HK1249009A1 (en) 2018-10-26
CN108396015B (zh) 2022-02-18
AU2016256582A1 (en) 2017-11-16
JP6928380B2 (ja) 2021-09-01
HRP20200439T1 (hr) 2020-06-12
CL2018000587A1 (es) 2018-08-10
PE20181140A1 (es) 2018-07-17
US20170266243A1 (en) 2017-09-21
AU2016256582B2 (en) 2020-10-29
US20180042973A1 (en) 2018-02-15
CO2017010831A2 (es) 2018-02-28
SI3288573T1 (sl) 2020-06-30
MX2017013684A (es) 2018-08-28
SG10201803081TA (en) 2018-06-28
JP2018139586A (ja) 2018-09-13
KR20180022638A (ko) 2018-03-06
ES2780366T3 (es) 2020-08-25
CN107690479B (zh) 2022-02-18
CA2984038A1 (en) 2016-11-03
EA037611B1 (ru) 2021-04-21
IL255286B (en) 2021-01-31
US10548929B2 (en) 2020-02-04
SG10201901482XA (en) 2019-03-28
MY183703A (en) 2021-03-09
KR20240032177A (ko) 2024-03-08
DK3288573T3 (da) 2020-03-16
SA517390260B1 (ar) 2021-11-10
SMT202000222T1 (it) 2020-05-08
US20180140649A1 (en) 2018-05-24
JP2018514199A (ja) 2018-06-07
US20170056458A1 (en) 2017-03-02
KR102643574B1 (ko) 2024-03-06
EA201791971A1 (ru) 2018-04-30
AU2020223665A1 (en) 2020-09-10
WO2016174200A1 (en) 2016-11-03
US10124028B2 (en) 2018-11-13
US11000559B2 (en) 2021-05-11
CN108396015A (zh) 2018-08-14
US20190076493A1 (en) 2019-03-14
CL2017002731A1 (es) 2018-06-08
IL258044A (en) 2018-05-31
KR20180118249A (ko) 2018-10-30
ZA201801589B (en) 2019-10-30
PL3288573T3 (pl) 2020-05-18

Similar Documents

Publication Publication Date Title
PE20181140A1 (es) Adenovirus oncolitico que codifica una proteina b7
CO2018005945A2 (es) Adenovirus del grupo b que codifica un anticuerpo contra el complejo tcr o fragmento de este
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
CL2018001107A1 (es) Variantes del factor viii cpg reducido, composiciones y métodos y usos para el tratamiento de trastornos de la hemostasis.
UY35964A (es) Anticuerpos humanos para pd?1
PE20160244A1 (es) Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos
AR100419A1 (es) Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosómico
MX2017004664A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
BR112019002646A2 (pt) composições de poxvírus quimérico e usos das mesmas
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
MX384795B (es) Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
MX2018007237A (es) Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus.
UY35965A (es) Anticuerpos humanos contra pd?l1
PE20181206A1 (es) Construcciones especificas del higado, casetes de expresion del factor viii y metodos de uso de estos
AR102527A1 (es) Vacunas terapéuticas para hpv16
UY35718A (es) Anticuerpos anti-csf-1r: métodos de expresión de los mismos.
CL2015003199A1 (es) Peptidos terapeuticos
MX2019006722A (es) Construcciones de adenovirus de chimpance con antigenos de lyssavirus.
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
MX2022000222A (es) Vectores virales recombinantes que contienen la proteina menor del virus del sindrome reproductor y respiratorio porcino (prrsv) y sus metodos de elaboracion y uso.
AR102301A1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
MX362515B (es) Proteinas péptidos y métodos de uso de las plantas antifúngicas.
MX2018000845A (es) Vector vírico orf recombinante.
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.